Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, raised $436 million in an upsized initial public offering (IPO) priced at the top of a marketed range. The Salt Lake City-based company sold about 24 million shares on Thursday for $18 each, according to data compiled by Bloomberg. The company, which marketed the shares for $16 to $18, twice earlier Thursday increased the number of shares to be sold.

• Technocraft Industries Hits Day High, Q2 Revenue Up 29%
• InCred Capital Acquires Quintessentially India to Expand Services
• Ola Fined Rs 10 Lakh Over Advance Tip Prompts for Rides
• Tata Motors PV Posts Rs 5,531 Cr Q2 Loss on JLR Costs
• Kanoria Chemicals Hits Day High as Q2 Profit Jumps 258%

Recursion reached a deal with Bayer AG in September to use AI to find new drugs for lung fibrosis and other fibrotic diseases. The deal included a $30 million upfront payment and $50 million in equity funding by Bayer’s investment arm. An investment arm of Bayer led a $239 million funding round for Recursion in September, according to a statement at the time. The company’s investors include Baillie Gifford and Mubadala, among others. The offering is being led by Goldman Sachs Group Inc. and JPMorgan Chase & Co. The shares are expected to begin trading Friday on the Nasdaq Global Select Market under the symbol RXRX.